Anteris Technologies Global Corp. Stock 12‑Month Price Target Cut to $12.84, Implies 93% Upside

Anteris Technologies Global Corp.'s average price target was reduced by analysts from $13.04 to $12.84, with a range of $9.19 to $16. This implies a 93% upside from the Oct. 12 closing price. The consensus rating remains 'Buy' among 6 analysts.

Original reporting
Published Oct 13, 2026, 10:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 10:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Anteris Technologies Global Corp. Stock 12‑Month Price Target Cut to $12.84, Implies 93% Upside — source image
Decision brief

The 30-second read

Low
01

Why it matters

Minor downward revision suggests limited near‑term price pressure but no material catalyst.

02

Market read

Small analyst downgrade with modest upside potential; unlikely to move market broadly.

03

What to watch

Lack of new company‑specific data; the cut is driven by broader market bias.

Relevance 4/10Novelty 4/10Timing: same-day release

Background

Analyst consensus price target for Anteris Technologies Global Corp. lowered from $13.04 to $12.84.

Market effects

none

none

none

Counterpoint

Price target cuts may reflect short‑term analyst sentiment rather than fundamental shift.

Key entities

  • Anteris Technologies Global Corp.

    Subject of analyst price‑target revision.

Related articles

$AVRMed

Anteris Advances DurAVR Toward Commercialization; PARADIGM Trial Expands U.S. Recruitment

Anteris Technologies Global Corp. (AVR) reported Q2 2026 results and said it secured U.S. Medicare reimbursement eligibility for PARADIGM Trial procedures. The company began U.S. recruitment, with first patients treated in May 2026, and said the trial is recruiting in the U.S., Denmark and the Netherlands. Net operating cash outflow was $20.8M; R&D expense was $23.4M.

$AVRMed

Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway

Anteris Technologies (ASX:AVR, NASDAQ:AVR) said it advanced its pivotal PARADIGM Trial in the June quarter, enrolling and treating its first US patients after CMS Medicare reimbursement eligibility for qualifying procedures. Recruitment expanded to the US, Denmark and the Netherlands, with Canada and France receiving regulatory clearance. The trial targets about 1,000 patients. Net operating cash outflows were US$20.8m.

$AVRMedAI 8/10

Anteris Technologies Announces Results for the Second Quarter of 2026

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) reported Q2 2026 results for the quarter ended June 30, 2026. It said CMS granted Medicare reimbursement eligibility for the PARADIGM Trial, U.S. recruitment began with first patients treated in May 2026, and the trial expanded to multiple regions. Net operating cash outflows were $20.8M; R&D expenses were $23.4M.

$AVRLow

Anteris Technologies Announces Results for the Second Quarter of 2026

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anteris Technologies Announces Results for the Second Quarter of 2026 MINNEAPOLIS, United States and BRISBANE, Australia August 12, 2026 (AEST) Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committe